Purpose Centrally authorised medicinal products (CAMPs) in the European Union may offer added therapeutic value (ATV) but may be linked to high prices and limited efficiency. Health technology assessment (HTA) and managed entry schemes (MES) may facilitate the reimbursement decision by providing reliable estimates of the medicinal product's value and costs and by controlling the remaining uncertainty, respectively. We investigated the impact of HTA criteria and the initiation of a MES on the reimbursement decision of CAMPs in Belgium. Methods We selected all reimbursement submissions for new centrally authorised medicinal products in the 2010-2015 period. We retrieved data relating to the reimbursement decision, the HTA outcome and the use of a managed entry scheme. Results The decision of the Minister was available for 115 dossiers, covering 36 (31.3%) orphan medicinal products (OMPs) and 79 ATV products. A MES was used in 41 submissions. A positive reimbursement decision was obtained in 65% of cases. The significant factors affecting the reimbursement decision were the approval of ATV, the medical need if it was considered 'important or major' and the use of a managed entry scheme. Price, budget impact and efficiency had no significant impact. Conclusions Added therapeutic value and high medical need increase the odds for a positive reimbursement decision. No impact could be demonstrated of the cost-related HTA criteria. Cost elements may be biased by the use of a confidential MES. Without a MES, only 53% of the centrally authorised medicinal products, including OMPs, are reimbursed in Belgium.
Introduction
Pricing and reimbursement of medicinal products remain a c o m p e t e n c e o f e a c h E u r o p e a n m e m b e r s t a t e . Reimbursement is diverse across member states in process, content and format; process transparency, health technology assessment (HTA) and required clinical evidence, interaction possibilities, timelines and formal language requirements are member state specific.
The heterogeneity in assessment and appraisal procedures should not exempt the member states to work in an objective and verifiable way in compliance with the Transparency Directive [1] . The European High Level Pharmaceutical Forum (HLPF) of 2005-2008 recommended in its conclusions [2] to rank medicinal products based on their added therapeutic value and to identify and reward valuable innovation. The Cross-Border Directive [3] stipulates (Article 15) that Bthe European Union shall support and facilitate cooperation between national authorities or bodies responsible for health technology assessment designated by the Member States^. Finally, the joint action programme of the European Commission builds on an effective, voluntary and sustainable collaboration on HTA across the competent authorities and between regulators and national HTA agencies, with the European network on HTA agencies (EUnetHTA) [4] as the coordinating actor.
In this work, we focused on the Belgian pharmaceutical reimbursement procedure. We investigated the impact of HTA and the use of a managed entry scheme (MES) [5] on the reimbursement decision of new medicinal products centrally authorised by the European Commission in the 2010-2015 period.
The reimbursement procedure [6] [7] [8] starts with the submission of a dossier for a new medicinal product by the applicant. The Commission on Reimbursement of Medicines (CRM) will review this submission in two phases. The first phase relates to the assessment of the new product as compared to the alternatives using HTA criteria of the core template proposed by EUnetHTA. A relative effectiveness assessment is always performed while a cost-effectiveness assessment is restricted to those medicinal products where the applicant claims added therapeutic value (ATV) compared to the alternatives (e.g. better efficacy, less toxicity). The second phase relates to the reimbursement proposal of the CRM which may be positive (approval), negative (refusal) or positive with restrictions (e.g. limiting the number of eligible patients). The CRM proposal is submitted to the Minister of Social Affairs who has the authority to make the final decision. The Minister's decision on the reimbursement may endorse the CRM proposal, or it may deviate from the proposal in either direction. Since 2010, managed entry schemes, which are conditional access schemes that handle relative effectiveness or cost-effectiveness uncertainties, have been included in the reimbursement track. A detailed description of the reimbursement procedure is provided as a supplementary material.
Objectives
As a primary objective, we investigated the impact of HTA elements ((added) therapeutic value, medical need, budget impact and efficiency) on the reimbursement decision of innovative medicinal products. As a secondary objective, we explored the link between the above-mentioned variables and the initiation of a MES and analysed the impact of a MES on the reimbursement decision.
Methods

The data analysis
Using the administrative database from the National Institute for Health and Disability Insurance, we selected all submissions from January 1, 2010, onwards, and for which the procedure ended by July 31, 2015. We selected products submitted as class 1 (a product for which the applicant claims ATV) or as OMP and excluded 'me-too' products and copies or generic products. The data set included the following variables: Descriptive statistics for the HTA elements and the use of a MES, and univariate analyses (chi-square test, odds ratios, Wilcoxon Rank Sum test) with the reimbursement decision were provided. Logistic regression (stepwise forward method) was used to analyse the simultaneous effects of the criteria on the reimbursement decision. A balance had to be considered on the number of independent variables included in the model; the aim was to increase precision, without limiting the power of the analysis because of missing data. Collinearity diagnostics included the estimation of the variance inflation factor (VIF < 2 to minimise collinearity).
Results
In the considered time frame, we retrieved 121 submissions. The main therapeutic areas were cancer and immunology (39.7%), neurology (14.0%), blood and blood-forming conditions (12.5%), systemic infections (9.2%) and alimentary tract and metabolic disease (7.5%). For OMP submissions, the percentage of cancer and immunology products increased to 59.5% (p = 0.003 versus non-OMP).
The reimbursement decision was available for 115 (95.0%) dossiers, covering 36 (31.3%) submissions for OMPs and 79 (68.7%) for class 1 products. The reimbursement decision is tabulated in Table 1 .
Overall, a positive reimbursement decision was obtained in 65.2% of cases, 67.1% of class 1 submissions and 61.1% of OMP submissions. The positive decision was in line with the applicant's request in only 4 class 1 and 5 OMP submissions. The use of a managed entry scheme was initiated in 41 submissions (35.6%).
For only 39 (49.4%) class 1 submissions, the CRM formally endorsed the claim of added therapeutic value.
The extent of medical need expressed as 'Service Médical Rendu' was considered 'major or important', 'moderate or weak' and 'insufficient' in 67.6%, 24.8% and 7.6% of submissions, respectively.
The mean and median annual budget impact for the health insurance were 6.7 Mio€ and 2.7 Mio€, respectively; the median budget impact was lower for OMP submissions (1.4 Mio €) than for class 1 submissions (4.0 Mio€) (p = 0.045).
The assessment of efficiency was done by an assessment of the ICER of the pharmaco-economic analysis submitted by the applicant because it was documented in 56 (66.7%) relevant cases as opposed to only 11 (13.1%) ICER estimates calculated by the commission. The mean and median ICERs were estimated at 32,419 € and 15,921 €, respectively, per QALY or LY; the ICER was negative in 5 cases meaning that the applicant claimed that the new product was more efficacious at a lower cost than the comparator.
Univariate associations: factors affecting the reimbursement decision of the Minister
The ATVendorsement by the CRM increased significantly the odds for a positive reimbursement decision, the estimate of the odds ratio (OR) and its 95% confidence interval (95% CI) was 7.2 (2.3-23.1] (p < 0.001). The reimbursement decision was significantly linked to the SMR (p = 0.004); only 28.6% of products with SMR 'insufficient' obtained reimbursement as opposed to 50.0% and 76.8% of products, respectively, with SMR being 'weak/moderate' or 'major/important'.
The reimbursement decision was associated with the estimated budget impact based on the price requested by the applicant (p = 0.022). A positive decision was linked to a lower median budget impact (1,800,000 €) than that from a negative decision (4,748,543€). The use of an Article 81 procedure was linked to submissions with a higher budget impact (p = 0.026); the difference in median budget was 3.9 Mio Euro.
The reimbursement decision was statistically unaffected by the ICER submitted by the applicant (p = 0.662).
The use of a MES did affect the probability of a positive decision and is detailed in Table 2 .
The probability of a positive reimbursement decision significantly increased from 52.7% without to 87.8% with a MES. The common odds ratio (95% CI) is estimated to be 6.3 (2.2-17.7) (p = 0.001) which illustrates the substantial effect size, both for OMPs and class 1 products.
Multivariate associations: factors affecting the reimbursement decision of the Minister
The results from the multivariate logistic regression analysis are detailed in Table 3 :
The variables having a significant impact on the odds for a positive reimbursement decision are Budget impact (p = 0.931), as submitted by the applicant, had no effect on the odds for a positive decision. Efficiency was not inserted in the model because of too many missing data. The variance inflation factor of the independent variables in the final model did not exceed 2 indicating collinearity might not be critical to the analysis.
Alternative logistic regression analyses have been conducted. If the analysis was done on class 1 submissions only, the model selected the same variables as significant predictors of the reimbursement decision with similar effect sizes; SMR, the use of a MES and the granting of ATV.
When the analysis was repeated on submissions without Article 81 procedure, the model selected SMR and the type of medicinal product (class 1 with ATV, OMP) as significant predictors of the reimbursement decision with effect sizes in line with the main analyses. [10] in which there was a median annual submission rate of 18 class 1 products and 6 OMPs. The observed reimbursement ATC codes are similar to the ATC codes observed in the EMA- [11] centralised procedure outcome in 2010-2015 which were immunooncology, followed by the areas of neurology, haematology and metabolic diseases. The respiratory area, which is among the five most frequent authorised categories, appeared only once in the reimbursement dataset (roflumilast, indicated in COPD); in the respiratory area, market authorization apparently did not generate added value reimbursement claims.
Impact of HTA elements
The percentage of positive decisions for class-1 products (67%) is close to the 69% obtained in the beginning (2002) (2003) (2004) (2005) (2006) (2007) of the CRM functioning [10] . The approval of the added therapeutic value strongly affects the reimbursement decision. The odds ratio for a positive decision is 13.7 if ATV is endorsed as compared to if it is refused. Products with ATV are rewarded by a positive reimbursement decision, in line with the HLPF recommendations [2] . The impact of ATV on the decision was already present in the early CRM activity [8, 10] .
Opposed to this, the percentage of positive decisions for OMPs has substantially decreased from 88% in the first 5 years of the CRM activity to 61% in the present study period (p = 0.021). OMPs, by being authorised, should express a 'significant benefit' [12] to patients suffering from a rare disease. This 'significant benefit', further defined as 'a clinically relevant advantage or a major contribution to patient care', explains that OMPs are by default granted an additional clinical benefit by the German [13] Federal Joint Committee.
Various factors could explain the observed declined willingness to reimburse OMPs. The impact of OMPs on the health insurance expenses have substantially increased [14] , from less than 100 million euro in 2007 to more than 250 million Euro in 2014, reflecting an annual increase of nearly 25 million euro. OMPs may suffer from competition from cheaper (compounded) alternatives. High priced OMPs reflect what the market is willing [15] to bear and these may be appreciated negatively [16, 17] .
Nearly 60% of OMP submissions are in the oncology and immunology area as opposed to 40% in the 2002-2007 period; the increased number of oncology medicines and their extended treatment duration-sometimes lifelong-may be a threat to the health insurance [18] . All these issues may have created a perception that the financial hurdle of OMPs is not proportional to their added value, decreasing the willingnessto-pay.
In all analyses, the extent of the disease medical need, approximated by the French SMR rating, appeared to be a strong predictor of the reimbursement decision, less than 30% of positive decisions if the SMR is considered insufficient but nearly 80% of positive decisions if it is considered major or important. The CRM evaluates the disease characteristics and the medical need in a narrative way, including descriptions of the target patient population, the clinical guidelines and the unmet medical need considering the existing alternatives if any. For future dossiers, this narrative medical need documentation could be linked to the disease priority list made by the local HTA agency [19] for early temporary reimbursement schemes; top priority diseases are identified based on the lack of beneficial treatments and the extent of the unmet medical need. Univariate analyses indicated that an increasing budget impact is associated to a negative reimbursement decision. The budget impact estimated by the applicant may be a weakness in our analyses; during the reimbursement procedure, limits applied to the size of the patient target group or to the proposed treatment dosing and duration will reduce the estimated budget impact. Applying limits to the reimbursement claim is common practice, as only 5% and 13% of the class 1 products and OMPs, respectively, obtain a positive reimbursement decision without any deviation in price or patient target group as compared to the applicant's submission. A clear illustration of this are the reimbursement conditions of the new anti-HCV products such as sofosbuvir, limiting the target population to specific genotypes and hepatic disease stages [20] .
Additionally, the use of MES interferes with the interpretation of the net budget impact because of the confidential financial compensation mechanisms towards the health insurance in such case.
The efficiency analysis in our study considered the ICERs computed by the applicant, because the CRM-estimate was often missing. ICERs estimated by applicants may be lower than those estimated by competent authorities; ICERs computed by applicants may be biased even if there is no formal ICER threshold in the Belgian reimbursement setting. Implicitly, it is admitted that high ICERs will generate increased pressure on the price but without resulting in our study in a statistical association with the reimbursement decision. The very limited number of ICERs estimated by the CRM is regrettable; in our opinion, this illustrates that the CRM is not focusing with the same resources on this health economic HTA criterion than it does on other HTA criteria relating to relative effectiveness. The efforts done to critically assess the budget impact of new medicinal products would benefit from an associated and equally critical health economic assessment to facilitate decisions for new medicinal products requiring incremental pharmaceutical budgets, but some of these may turn out to be cost-effective from the healthcare perspective.
The use of a MES
The impact of the use of a managed entry scheme on the reimbursement decision is substantial. MES is a tool to handle uncertainties. The available evidence at first listing of OMPs is often limited [21] . Moreover, most so-called innovative products are considered not offering incremental therapeutic value [22] or may suffer from low efficiency yielding a threat to affordability [23, 24] . Our results indicate that, among the reimbursement submissions without a MES, the overall percentage of positive decisions is only slightly above 50%. This percentage of positive decisions increases to 88% if a MES is used and the OMPsuccess rate becomes comparable to the one observed in the first 5 years of CRM activity.
This increase in the percentage of positive decisions is remarkable because it refers to more complex product submissions. Apparently, the financial compensation towards the health insurance agency (estimated to be 26.3% of the product's expected budget impact according to the NIHDI report [14] ), the opportunity for the applicant to safeguard the list price and the confidential nature of the negotiation, allows competent authorities and applicants to negotiate a positive reimbursement outcome which would not be achieved without a MES setting.
As of February 1, 2018, a new legislation has extended the use of managed entry schemes [25] . If a product is subject to a MES at first listing, additional authorised indications can be added directly into an adapted reimbursement MES without the need to go through the regular CRM procedure. The greatest benefit of a managed entry scheme is probably that it offers access to innovative technologies which otherwise would not happen. The major drawbacks of a MES are its disturbing effect on market dynamics [26] , the lack of transparency in the decision-making and the extra workload because at the end of the temporary reimbursement scheme, new decisions must be made based on updated assessments.
Conclusions
Added therapeutic value and high medical need increase the odds for a positive reimbursement decision. No impact could be demonstrated of the cost-related HTA criteria even if there is some evidence that increasing the budget impact may lower the odds for a positive decision. The cost-effectiveness data suffered from poor quality. The use of a MES is highly supportive to obtain reimbursement of innovative medicinal products in Belgium. Without MESs for OMPs, the percentage of positive reimbursement decisions would be significantly lower than the percentage observed in the early years of the functioning of the reimbursement commission.
